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Research
Estimation of health risks associated with
environmental exposure to low doses of toxi-
cants is essential to improving human health
risk assessment. As such, the Commission on
Risk Assessment and Risk Management of
the National Research Council (NRC 1997)
has recommended development of environ-
mental research and management tools. The
science made possible through proteomic
analysis provides a useful investigative tool to
accomplish these recommendations through
simultaneous analysis of numerous proteins
in one sample. Through this approach, it is
possible to detect molecular changes associ-
ated with low-dose environmental exposure
before the development of clinically apparent
disease. By using patterns of changes in these
proteins measured simultaneously, it is also
possible to deduce mechanisms of action in
the pathologic development of disease. These
mechanisms can be compared between differ-
ent toxicants and biological systems, includ-
ing humans, human cell lines, and rodents.
One toxicant that is both relevant and far
reaching in human exposure is arsenic. Arsenic
is a naturally occurring metalloid found in
water, soil, and air, and exposure to inorganic
As occurs through both environmental and
occupational sources (International Agency
for Research on Cancer 1987). Epidemiologic
studies have associated As ingestion with
an increased risk in many human cancers,
including lung, skin, bladder, kidney, liver,
and stomach (Chiou et al. 1995; Wu et al.
1989). Arsenic is also associated with non-
malignant diseases such as peripheral vascular
disease (Chiou et al. 2005), diabetes (Navas-
Acien et al. 2006), and chronic lung disease
(Smith et al. 2006). Although chronic expo-
sure to moderate and/or high levels of As in
drinking water may lead to the development of
cancer in humans, the effects of lower, envi-
ronmentally relevant doses are only inferred
through models of high exposure. There is lit-
tle data evaluating the molecular effect of
chronic, low-dose As exposure. This is partly
due to the absence of measurable end points in
this process. 
The molecular and cellular mechanisms
by which As acts as a toxicant have not been
clearly elucidated, although as a carcinogen, it
appears to act through epigenetic mecha-
nisms. Arsenic has been implicated in promot-
ing alterations in multiple cellular pathways,
including growth and proliferation pathways,
apoptotic pathways, DNA repair mechanisms,
immunosurveillance, and stress–response
pathways (Rossman 2003). 
In As-exposed experimental systems, alter-
ations accompanying transformation to the
malignant phenotype have been deﬁned utiliz-
ing cDNA microarray technology to charac-
terize gene expression (Chen et al. 2001; Lu
et al. 2001). Altered genes implicated a number
of cell mechanistic pathways including cell-
cycle regulation, signal transduction, stress
response, and apoptosis, as well as cytokine,
growth factor, and hormone receptor genes. 
Microarray analysis has been used for
global determination of As-induced altera-
tions, but the relationship between transcripts
and the proteome is not easily transferred
(Chen et al. 2003). Because it is ultimately the
change in protein expression that alters the
cellular response, evaluation of the proteome
may allow for a more direct measure of As
effects. Methods for analyzing multiple pro-
teins have greatly advanced in the last several
years with the ability of mass spectrometry
(MS) and tandem MS (MS/MS) to analyze
peptides extracted following protein isolation
using two-dimensional (2-D) gel elec-
trophoresis and proteolytic digestion. These
techniques have the advantage that proteins
are much more stable than mRNA obtained
from human populations and that post-
translational modiﬁcation of selected proteins
can be detected using MS-based proteomic
techniques. In addition, lung-lining ﬂuid may
provide a source to detect lung-specific
changes in protein response to toxicant expo-
sures. Use of 2-D gel electrophoresis to exam-
ine alterations in protein expression in mouse
epithelial lining fluid in ozone-sensitive and
ozone-resistant mice has been reported
(Wattiez et al. 2003). Previous proteomics
studies involving As have relied on in vitro
studies of single cell cultures (He et al. 2003;
Lau et al. 2004). To our knowledge, no such
data exist for As-induced changes in expres-
sion of proteins in lung-lining ﬂuid. 
In this article, we report As-induced
changes in lung-lining ﬂuid proteins of mice
that occur after chronic, low-level exposures.
To date, data obtained from animal research
has been used to validate one of the potential
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OBJECTIVE: Environmental exposure to arsenic results in multiple adverse effects in the lung. Our
objective was to identify potential pulmonary protein biomarkers in the lung-lining ﬂuid of mice
chronically exposed to low-dose As and to validate these protein changes in human populations
exposed to As. 
METHODS: Mice were administered 10 or 50 ppb As (sodium arsenite) in their drinking water for
4 weeks. Proteins in the lung-lining ﬂuid were identiﬁed using two-dimensional gel electrophoresis
(n = 3) or multidimensional protein identification technology (MUDPIT) (n = 2) coupled with
mass spectrometry. Lung-induced sputum samples were collected from 57 individuals (tap water As
ranged from ~ 5 to 20 ppb). Protein levels in sputum were determined by ELISA, and As species
were analyzed in ﬁrst morning void urine.
RESULTS: Proteins in mouse lung-lining fluid whose expression was consistently altered by As
included glutathione-S-transferase (GST)-omega-1, contraspin, apolipoprotein A-I and A-IV,
enolase-1, peroxiredoxin-6, and receptor for advanced glycation end products (RAGE). Validation of
the putative biomarkers was carried out by evaluating As-induced alterations in RAGE in humans.
Regression analysis demonstrated a signiﬁcant negative correlation (p = 0.016) between sputum levels
of RAGE and total urinary inorganic As, similar to results seen in our animal model. 
CONCLUSION: Combinations of proteomic analyses of animal models followed by speciﬁc analysis of
human samples provide an unbiased determination of important, previously unidentiﬁed putative
biomarkers that may be related to human disease. 
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exposed to As.
Materials and Methods
All chemicals and reagents were purchased
from Sigma Chemical Company (St. Louis,
MO) unless otherwise noted.
Animal exposure. Male C57B16 mice
from Jackson Laboratories (Bar Harbor, ME),
21 days of age, were exposed to As through
drinking water for a total of 4 weeks. A total
of 15 animals were split into three exposure
groups: 50 ppb As, 10 ppb As, and a control
group (water only, pH 7.0). Water for the
50-ppb and 10-ppb As treatment groups was
prepared from sodium arsenite and the pH
was adjusted to 7.0 with hydrochloric acid
and sodium hydroxide. Water was adminis-
tered to the animals 3 days weekly (Monday,
Wednesday, Friday). Concentrations of As,
were validated by inductively coupled plasma
(ICP)-MS analysis. All animals were treated
humanely and with regard for alleviation of
suffering. All protocols were approved by the
institutional animal care and use committee.
Bronchoalveolar lavage. At the end of the
4-week exposure, animals were sacrificed by
carbon dioxide exposure, and bronchoalveolar
lavage (BAL) fluid (BALF) was collected as
described by Wattiez et al. (2003). 
Acetone precipitation. Proteins were pre-
cipitated overnight in an 80% acetone solu-
tion prepared with HPLC grade acetone. The
solution was then centrifuged for 10 min
(5 × g at 4°C) to remove protein from the
solution. The pellet was rinsed twice with
3 mL HPLC grade acetone at 4°C for 5 min
each wash cycle (5 × g at 4°C).
Determination of protein concentration.
Protein concentrations were determined using
the Coomassie Plus Assay Kit (Pierce,
Rockford, IL). Bovine serum albumin was
used as the standard. Samples were diluted in
200-µL aliquots of ultra-pure water before
protein cleanup. 
Protein cleanup. We split each 200-µL
sample into two 100-µL cleanup volumes.
Samples were purified using a Bio-Rad
ReadyPrep 2-D Cleanup Kit (163-2160; Bio-
Rad, Hercules, CA) following the manufac-
turer’s instructions. After cleanup was
complete, samples were rehydrated with Bio-
Rad ReadyPrep 2-D Rehydration/Sample
Buffer 1 (7 M urea, 2 M thiourea, 1% amido-
sulfobetaine-14, 40 mM Tris). Samples were
diluted to a 500 µg/mL concentration for
analysis by the Southwest Environmental
Health Science Center/Arizona Cancer Center
Proteomics Core. 
Western blots. Mouse BAL samples were
suspended in Laemmli buffer and run on
12.5% SDS-PAGE. Samples were transferred
to nitrocellulose and blotted with anti-RAGE
(receptor for advanced glycation end products)
antibody (R&D Systems, Minneapolis, MN)
followed by horseradish peroxidase–linked sec-
ondary antibody (Sigma). Blots were devel-
oped with the SuperSignal West Femto kit
(Pierce). We determined band density using
the Chemidoc XRS system under Quantity-
one software control (Bio-Rad).
2-D gel electrophoresis. We submitted
three samples from each exposure group
(200 µL containing 100 µg protein) for 2-D
SDS-PAGE separation. Each sample was run
on an 11-cm immobilized pH gradient strip,
pH 5–8, and then resolved on 12.5%
Tris-HCl gel. Gels were stained using silver
solution (2.5% wt/vol silver nitrate and 37%
wt/vol formaldehyde) for 20 min.
Image acquisition and analysis. Stained gels
were imaged using an Investigator ProPic and
HT Analyzer software, both from Genomic
Solutions (Ann Arbor, MI). Intensity was cali-
brated with an intensity step wedge before the
image was taken, and spot intensity was nor-
malized with background subtraction. Gels
were overlaid using Phoretix 2-D Expression
software (Nonlinear Dynamics, Durham, NC).
Gels for controls and treated groups were super-
imposed and stretched to match corresponding
spots on each gel. Spots that varied by intensity,
appeared to be shifted, or were absent from
either group were picked robotically and saved
for mass spectrometry identiﬁcation. 
Liquid chromatography (LC)-MS/MS
analysis. Excised protein spots were destained
in a 1:1 mixture of 30 mM potassium ferro-
cyanide and 100 mM sodium thiosulfate.
Samples were digested in trypsin (10 µg/mL)
overnight at 37°C. LC-MS/MS analyses were
carried out using a quadrupole ion trap
ThermoFinnigan LCQ DECA XP PLUS
(ThermoFinnigan, San Jose, CA) equipped
with a Michrom Paradigm MS4 HPLC
(Michrom Biosources, Auburn, CA) and a
nanospray source. Peptides were eluted from a
15-cm pulled tip capillary column (100 µm
i.d. × 360 µm o.d; 3–5 µm tip opening)
packed with 7 cm Vydac C18 (Vydac,
Hesperia, CA) material (5 µm, 300Å pore
size), using a gradient of 0–65% solvent B
(98% methanol/2% water/0.5% formic
acid/0.01% triﬂouroacetic acid) over a 60-min
period at a ﬂow rate of 350 nL/min. The elec-
trospray ionization–positive mode spray volt-
age was set at 1.6 kV, and the capillary
temperature was set at 200°C. We performed
data-dependent scanning using Xcalibur, ver-
sion 1.3, software (ThermoFinnigan) as
described by Andon et al. (2002); we used a
default charge of 2, an isolation width of
1.5 amu, an activation amplitude of 35%, an
activation time of 30 msec, and a minimal sig-
nal of 10,000 ion counts. Global dependent
data settings were as follows: reject mass width,
1.5 amu; dynamic exclusion enabled; exclusion
mass width, 1.5 amu; repeat count, 1; repeat
duration, 1 min; and exclusion duration,
5 min. Scan event series included one full
scan with mass range 350–2,000 Da, fol-
lowed by three dependent MS/MS scans of
the most intense ion. MS/MS spectra were
analyzed with Turbo SEQUEST, version 3.1
(ThermoFinnigan), a program that allows the
correlation of experimental MS/MS data with
theoretical spectra generated from known
protein sequences. The peak list for the search
was generated by Xcalibur 1.3. Parent peptide
mass error tolerance was set at 1.5 amu, and
fragment ion mass tolerance was set at
0.5 amu during the search. All spectra were
searched against the latest version of the non-
redundant protein database downloaded 14
July 2005 from the National Center for
Biotechnology Information (NCBI 2005).
We used X!Tandem (Global Proteome
Machine Organization, Vancouver, British
Columbia, Canada), to validate protein identi-
fication and as a means of highlighting false
positive protein identiﬁcations by searching the
data with a “reversed” version of the protein
database (Craig et al. 2004). Proteins found
during the reversed search were subsequently
removed from the protein list. 
MUDPIT analysis. We analyzed two
additional samples from each exposure group
by multidimensional protein identification
technology (MUDPIT). For these complex
protein samples, ammonium bicarbonate was
added to a concentration of 0.1 M; 40 µL of
10 mM DTT was then added before reducing
at 56°C for 45 min (Wolters et al. 2001).
Reduced cysteines were alkylated by addition
of 40 µL of 55 mM iodoacetamide (10 mM
ﬁnal concentration) and incubated for 30 min
at room temperature. Proteolysis was initiated
with a 1:25 ratio (by weight) of sequencing
grade modified trypsin and allowed to pro-
ceed overnight at 37°C. The digest was stored
at –20°C until analysis.
For MUDPIT, we used a microbore
HPLC system (Paradigm MS4; Michrom,
Auburn, CA) with two separate strong cation
exchange and reversed phase columns: a 100
µm I.D. capillary packed with 7 cm of 5 µm
Vydac C18 reversed phase resin and a separate
250 µm I.D. capillary packed with 7 cm of 5
µm Partisphere strong cation exchanger resin
(Whatman, Clifton, NJ). The sample (4.36
µg) was acidified using trifluoroacetic acid
(TFA) and manually injected onto the strong
cation exchange column, the efﬂuent from the
column being fed through reversed phase col-
umn. A representative 12-step MUDPIT
analysis includes the following solutions: 10%
methanol/0.1% formic acid, 0.01%TFA
(buffer A); 95% methanol/0.1% formic acid,
0.01% TFA (buffer B); 10% methanol/0.1%
formic acid, 0.01% TFA (buffer C); and
500 mM ammonium acetate/10% methanol/
0.1% formic acid, 0.01% TFA (buffer D).
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at 100% buffer A, another equilibration step
for 5 min at 25% buffer B (75% buffer A), and
a 40 min gradient from 25% buffer B to 65%
buffer B, followed by 10 min 65% buffer B
and 10 min 100% buffer A. Chromatography
steps 2–12 followed the same pattern: 15 min
of the appropriate percentage of buffers C and
D followed by a 2-min 100% buffer C wash, a
5-min wash with 100% buffer A, equilibration
with 25% buffer B for 5 min, a gradient from
25% buffer B to 65% buffer B in 40 min; and
finally a 10-min 65% buffer B wash and a
10-min 100% buffer A wash. The buffer C/
buffer D percentages used were 95/5%,
90/10%, 85/15%, 80/20%, 70/30%, 60/40%,
40/60%, 20/80%, 0/100%, 0/100%, and
0/100% for the 11 salt steps. MS/MS and
database searching conditions were the same as
those described above (Andon et al. 2002). We
used DTASelect (Tabb et al. 2003) to ﬁlter the
results according to previous criteria for reliable
sequence peptides (Hunter et al. 2002; Wolters
et al. 2001). 
Human study. This study was approved by
the institutional review board at the University
of Arizona. Study methods have been reported
elsewhere (Josyula et al. 2006). Brieﬂy, house-
hold recruitment took place between June
2002 and August 2003 in Ajo, Arizona (tap
water As, ~ 20 ppb), and Tucson, Arizona (tap
water As, ~ 5 ppb). Inclusion criteria required
at least 3 years continuous residence at the time
of recruitment, use of tap water for drinking
and food preparation, and no current smoking.
Information related to demographics, medical
history, and occupational and environmental
As exposures was collected. Information on
consumption of seafood and/or mushrooms
during the previous 3-day period was collected
to assess other potential sources of As exposure.
Sample collection. A first morning void
urine sample was collected in two sterile
120-mL screw-topped polypropylene contain-
ers, which were previously tested and deter-
mined to be As free. Urine samples were
processed within 2 hr of collection. For each
household, tap water from the cold water faucet
in the kitchen was allowed to run for 1 min
before collecting water into two sterile 50-mL
conical vials. Samples were stored at 4°C until
transported to the University of Arizona for As
analysis. An HPLC-ICP-MS speciation method
was modiﬁed for the measurement of As (Gong
et al. 2001). Urinary total inorganic As was
deﬁned as the sum of arsenite (As3+), arsenate
(As5+), monomethylarsonic acid (MMAV), and
dimethylarsinic acid (DMA). 
Sputum induction was performed as pre-
viously described by Burgess et al. (2002).
Subjects were asked to breathe a sterile 3%
saline aerosol (Baxter, Deerfield, IL) gener-
ated using DeVilbiss Ultra-Neb 99HD ultra-
sonic nebulizers (Sunrise Medical, Somerset,
Lantz et al.
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Table 2. MUDPIT analysis of proteins in BALF from control mice and mice exposed to 10 or 50 ppb As3+ in
their drinking water for 4 weeks. 
Present Accession No.  of  Percent 
Control 10 ppb 50 ppb Identiﬁed protein no.a peptides coverage
X X X Alpha-2-HS-glycoprotein AAH12678 3 18.0
X X X Apolipoprotein A-Ib  AAH19837 4 16.8
X X X Carboxylesterase precursor P23953 2 5.2
X X X Clara cell protein 10 AAH27518 1 14.3
X X X Contraspin (Serpina 3k)b  CAA40106 10 33.0
X X X GST omega 1b  AAH85165 2 10.0
X X X Hemopexin AAH19901 9 27.2
X X X Kininogen 1 AAH18158 1 1.4
X X X Plasminogen AAH57186 3 6.2
X X X Pregnancy zone protein AAH57983 3 2.5
X X X RAGEb  AAH61182 3 8.2
X X X Serpina 1a AAH37007 7 23.5
X X X Serpina 1b AAH25445 6 21.6
X X X Serpina 1d NP_033272 7 25.4
X X X Serpina 1e AAH61176 5 17.2
X X X Transferrin AAH22986 24 41.0
X X X Vtamin D-binding protein AAH51395 4 14.2
X X Aldehyde dehydrogenase 1A7 AAH46315 2 6.2
X X Complement component 3 AAH43338 5 4.9
X X Creatine kinase, muscle P07310 2 7.1
X X Gelsolin, cytosolic AAH23143 1 1.5
X X Igh-6 AAH99618 1 2.6
X X Inter-alpha trypsin inhibitor, heavy chain 2 AAH34341 2 3.5
X X Leucine-rich alpha-2-glycoprotein AAH92077 2 7.9
X X Mast cell protease 7 AAH11328 1 28.3
X X Murinoglobulin 1 AAH51037 2 1.8
X X Peroxiredoxin-6b  AAH13489 1 4.5
X X Serpinc1(antithrombin) AAH33377 1 2.2
X X Transthyretin AAH86926 3 34.7
X EGF-binding protein type A  NP_034244 2 7.7
X EGF-binding protein type B NP_034774 4 23.0
X Kallikrein 1-related peptidase b16  AAH12237 2 11.9
X Glyceraldehyde-3-phosphate dehydrogenase AAH92264 2 8.4
X Kallikrein 27 NP_064664 2 11.0
X Myoglobin AAH25172 2 20.8
X Nerve growth factor, gamma CAA25930 2 11.8
X Parotid secretory protein AAH53336 2 12.8
X Pyruvate kinase 3 AAH94663 2 5.8
X X Aldehyde dehydrogenase 1A1 AAH44729 1 2.9
X X Apolipoprotein A-II AAH31786 1 9.8
X X Apolipoprotein A-IVb  AAH50149 2 8.1
X X Apolipoprotein H AAH53338 1 4.1
X X Carboxylesterase 3 Q8VCT4 1 2.5
X X Fetub protein AAH18341 2 4.9
Two animals per dose were analyzed. Only proteins in which multiple peptides were identiﬁed or in which single peptides
were identiﬁed in multiple animals were considered positives; albumin and hemoglobins were excluded.
aAccession numbers from NCBI (2005). bProteins were also identiﬁed using 2-D gel analysis. 
Table 1. Proteins identiﬁed as being differentially expressed following 2-D SDS-PAGE/isoelectric focusing
separation of BAL proteins from control (n = 3) and As-treated (50 ppb; n = 3) animals. 
Gel, Accession  No.  of  Percent 
spot no. Identiﬁed protein no.a peptides coverage
Control
1 RAGE AAH61182 4 9.0
3 GST omega-1 AAH85165 2 7.9
10 Contraspin CAA40106 2 8.4
13 Apolipoprotein A-IV AAH50149 3 9.6
14 Apolipoprotein A-I AAB58426 4 17.5
50 ppb As
6 Peroxiredoxin-6 NP_031479 5 28.6
16 Enolase 1 AAH39179 5 16.8
17 Enolase 1 AAH39179 2 6.1
Spots differing in intensity and appearance were cut out of the gels, digested, and identiﬁed using MS. These qualitative
data give possible candidates for further analysis by quantitative methods. 
aAccession numbers from NCBI (2005). PA) set on maximum output. All sputum
supernatant samples were analyzed in dupli-
cate for levels of RAGE using commercially
available ELISA (R&D Systems). 
Statistical analysis. We used SPSS 12.0
(SPSS, Chicago, IL) and Stata 8.2 (StataCorp,
College Station, TX) software for statistical
analyses. For parametric tests, sputum RAGE
concentrations were normalized using natural
log transformations. Independent-sample t-tests
were used to compare population characteristics
by town, and RAGE concentrations by sex,
race, town, diabetes, ever-asthma, and past
smoking. Pearson’s correlation analyses were
used to assess correlations among the different
sputum biomarkers. We used multiple linear
regression models to assess the association of
urinary As and sputum RAGE, adjusting for
potential confounders. For each of the outcome
measures, variables found to be marginally sig-
niﬁcant in univariate regression analyses were
included in a stepwise regression model using a
backward elimination technique to decipher
ﬁnal models. Diagnostics were then performed
for each model to assess whether assumption
parameters for linear regression were met. To
account for possible confounding effects, we
included town, ever-asthma and MMAV/
(As3++As5+) in each model, regardless of their
statistical signiﬁcance. Town was forced into
the models to account for other environmental
or biological differences not assessed in this
study. Similarly, asthma was included to
account and adjust for known lung inﬂamma-
tion associated with the disease, and the ratio of
MMAV/(As3++As5+) was used as a measure of
active methylation of inorganic As.
Results
We used 2-D SDS-PAGE/isoelectric focusing
separation of BALproteins from controls (n =
3) and animals treated with 10 ppb (n = 3)
and 50 ppb As (n = 3) to identify protein
expression that was consistently altered by As.
To date, 25 spots have been analyzed (12 from
animals treated with 50 ppb As and 13 from
controls). Only proteins in which multiple
peptides were identified were considered
positively identiﬁed proteins. Identities of the
proteins of interest from the spots selected for
analysis are shown in Table 1. Identiﬁed pro-
teins with expression that decreased with As
exposure (higher intensity in the control gel or
absent in the As-treated gel) were RAGE,
glutathione-S-transferase (GST)-omega-1,
contraspin (a serine—or cysteine—proteinase
inhibitor isoform), apolipoprotein A-IV, and
apolipoprotein A-I. Arsenic induced increased
expression of both peroxiredoxin-6 and
enolase-1. 
Lavage proteins from two additional ani-
mals in each group were subjected to MUDPIT
analysis. Only proteins in which multiple pep-
tides were identiﬁed or in which single peptides
were identiﬁed in multiple animals were con-
sidered positively identiﬁed proteins. Albumin
and hemoglobins were excluded. Using these
criteria, a total of 44 proteins were identiﬁed
(Table 2). Six of the seven proteins identiﬁed
using the 2-D gels were also present in the
MUDPIT analysis (Table 2). Identiﬁcation of
these proteins by two distinct proteomic analy-
ses makes them excellent candidates for
dose–response quantitative analysis. 
We selected RAGE for further analysis
and validation because of its association with
chronic inflammatory diseases and the avail-
ability of commercial reagents. Data from
2-D gels suggested that As exposure resulted
in a decrease in BALF RAGE levels in mice.
Western blots verified this conclusion. Blots
from the same two animals used in MUDPIT
analysis showed a dose-dependent decrease in
band density of RAGE for samples exposed to
0, 10, and 50 ppb As (data not shown). 
Although animal models are useful for
discovery of potential biomarkers, these bio-
markers must be validated and tested in
human populations exposed to As. To evalu-
ate the effect of As using lung-speciﬁc, mini-
mally invasive techniques, we chose to
determine the effect of As on levels of RAGE
in human induced sputum. 
The tested subjects were part of a larger
study of 73 individuals who met inclusion crite-
ria (Josyula et al. 2006): 40 from 33 households
in Ajo and 33 from 30 households in Tucson.
Of these subjects, 57 (78%) provided sputum,
and there were no significant differences in
demographics, smoking history, asthma, or dia-
betes between subjects who did (n = 57) and
did not (n = 16) provide sputum samples. Of
the 57 subjects providing sputum, all had ade-
quate volumes for RAGE analysis. This popula-
tion of 57 subjects ranged in age from 30 to
92 years, and was predominantly female, over
66% non-Hispanic white, and college educated
(Table 3). The Tucson and Ajo populations did
not differ signiﬁcantly in age distribution, sex,
race, asthma or diabetes diagnoses, or past
smoking history. 
Sputum RAGE concentrations were not
significantly different by town (Table 3).
However, there was a marked overlap of uri-
nary total inorganic As concentrations across
the towns. Therefore, we compared sputum
RAGE concentrations with urinary total inor-
ganic As concentration, combining both
towns, as shown in Figure 1. Six individual
concentrations of RAGE were identified as
outliers using the method of Hadi (1992) for
multivariate data; five of these were below
detectable levels. Regression analyses were con-
ducted without and with these observations.
Table 4 displays results from regression analy-
ses excluding the deﬁned outliers. We found a
signiﬁcant negative association between urinary
total inorganic As concentrations and RAGE
Pulmonary protein biomarkers of arsenic exposure
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Table 3. Population data by town.
Characteristic Ajo Tucson p-Valuea
No. of subjects  34 23
Female 21 (62) 13 (57)
Age (years)
All 63.2 ± 15.6 65.4 ± 14.4
< 60 12 (35) 9 (39)
61–80 16 (47) 10 (44)
> 80 6 (18) 4 (17)
Ethnicity
Hispanic 13 (38) 6 (26)
White non-Hispanic 21 (62) 17 (74)
Personal history
Past smoking 15 (44) 11 (52)
Preexisting illness
Kidney 6 (18) 4 (17)
Ever asthma 12 (35) 13 (56)
Ever diabetes 7 (21) 2 (9)
Water As levels (n)2 9 2 1
Total water As (µg/L) 20.2 ± 3.6 4.0 ± 2.4 < 0.001
Urine As levels (n)3 4 2 2
Total urinary As (µg/) 27.4 ± 18.5 15.8 ± 15.7 0.019
Total urinary inorganic As (µg/L) 28.2 ± 20.5 13.0 ± 13.7 0.004
Urinary As3+ + As5+ (µg/L) 8.6 ± 9.0 6.0 ± 10.1 0.328
Total urinary MMAV (µg/L) 2.9 ± 3.9 1.1 ± 1.2 0.003b
Total urinary DMA (µg/L) 16.7 ± 11.7 5.8 ± 4.8 < 0.001b
Urinary MMAV/(As3+ + As5+) 0.73 ± 0.67 2.12 ± 3.79 0.572b
Creatinine-adjusted urinary As (µg/g)c 32.3 ± 13.3 16.1 ± 10.3 < 0.001
Sputum RAGE levels (n)3 4 2 3
RAGE (pg/mL) 5,473 ± 25,824 1,336 ± 1,260 0.662b
RAGE excluding regression outliers (pg/mL)  1,192 ± 962 1,396 ± 1,254 0.844b
Values shown are number (%) or mean ± SD, except where indicated. p-Value < 0.05 is statistically signiﬁcant. 
aCompared using independent sample t-test with normally distributed test variable, unless speciﬁed otherwise. bThe com-
parisons were performed using two-sample t-test with log-normalized variable data. cValid values: n = 12 for Ajo and n =
19 for Tucson. expression. Urinary total inorganic As was not
significant when the outliers were included;
however, the pentavalent form of As in urine
(As5+) was found to be signiﬁcant in this set-
ting (β = –0.304; p = 0.026). In addition, with
the outliers included, having diabetes became
significantly associated with sputum RAGE
(β = 1.93; p = 0.021), and the contribution of
body mass index (BMI) remained statistically
signiﬁcant. Asthma and the extent of methyla-
tion of As were not found to be associated with
RAGE in either model. Town was kept in the
model to account for potential differences in
environmental exposures between communi-
ties that were not measured in this study, even
though it was not statistically signiﬁcant.
To test whether As compounds would
directly bind to the receptor and interfere with
quantitative ELISA measurements, we added
50 ppb sodium arsenite or 5 ppb monomethy-
larsonous acid (MMAIII) to standards contain-
ing recombinant RAGE protein. Arsenic
addition did not interfere with the measure-
ment of RAGE levels (data not shown). To
evaluate whether ligands or proteases in the
induced sputum were affecting the levels of
measured RAGE, recombinant RAGE was
added to two sputum samples. No differences
were seen when these samples were compared
with RAGE standards (data not shown). 
Discussion
Discovery of biomarkers responsive to low-
dose environmental exposures will greatly
improve human health risk assessment. Using a
proteomics approach, we have used data col-
lected from animal models to drive evaluation
and validation in human protein samples col-
lected using minimally invasive techniques.
Several proteins were consistently altered in
2-D gels from mouse BALF. Six of these pro-
teins were also identiﬁed in MUDPIT analysis,
providing additional conﬁdence that they may
be important biomarkers of As exposure and
effect. We subjected one of these proteins,
RAGE, to further analysis. Western blot analy-
sis indicated an As-induced decrease in RAGE
in mouse BALF. Using quantitative ELISA
analysis, we veriﬁed that RAGE levels are also
altered as a function of As levels in human
populations. We have not yet analyzed the
other potential biomarkers in human samples.
RAGE is a multiligand member of the
immunoglobulin superfamily of cell surface
receptors (Bierhaus et al. 2005). In addition to
being a receptor for products of glycation and
oxidation of proteins and lipids, RAGE has
more recently been shown to bind other pro-
inflammatory ligands such as S100/calgran-
ulins, amphoterin, and amyloid-β-peptide
(Ramasamy et al. 2005). Levels of RAGE in the
lung are quite high, and expression has been
demonstrated on the basolateral surfaces of
alveolar epithelial type I cells (Shirasawa et al.
2004). RAGE has been recognized for its role
in several chronic diseases, such as diabetes, ath-
erosclerosis, coronary artery disease, and lung
cancer (Bierhaus et al. 2005; Falcone et al.
2005; Hofmann et al. 2004). In addition to the
membrane-associated receptor, a soluble form
of the receptor has been identiﬁed in mice and
humans [soluble RAGE (sRAGE)] (Hanford
et al. 2004). The presence of this soluble recep-
tor is thought to provide a binding site for
sequestration of ligands, thus reducing the cel-
lular effects of binding to membrane-associated
RAGE (Bierhaus et al. 2005). Plasma levels of
sRAGE have been found to be decreased in
association with the presence of coronary artery
disease in nondiabetic men (Falcone et al.
2005). Soluble RAGE is also decreased in
patients with rheumatoid arthritis, indicating
deﬁcient inﬂammatory control (Pullerits et al.
2005). In arthritic patients, addition of sRAGE
attenuated joint inﬂammation and expression
of inﬂammatory and tissue-destructive media-
tors (Moser et al. 2005). In a diabetic mouse
model, application of sRAGE reduced inﬂam-
mation, reduced skin wound healing times, and
decreased the protein and enzymatic activity
levels of matrix metalloproteinase-9 (MMP-9)
(Goova et al. 2001). Based on these known
actions of RAGE, alterations in levels of expres-
sion of this protein could contribute to As-
induced diseases such as chronic lung disease,
cancer, peripheral vascular disease, and diabetes.
Several mechanisms can potentially explain
the As-induced reductions in RAGE levels in
the lavage and sputum samples. Arsenic could
be directly binding to the sRAGE, inhibiting
recognition by the antibodies used in the
ELISA. This does not seem likely because
adding As3+ or MMAIII to samples containing
recombinant RAGE did not affect the mea-
sured levels. Arsenic could be altering the levels
of compounds that bind to the receptor or the
levels of proteases that degrade the receptor.
Both would be expected to reduce the measur-
able levels in the sputum samples. Again, this
seems unlikely because addition of recombinant
RAGE to sputum samples did not affect mea-
sured levels compared with controls. Finally, As
may change RAGE gene expression by altering
promoter region methylation or by affecting
transcriptional regulators of RAGE (Li and
Schmidt 1997; Tohgi et al. 1999). 
We have previously reported from the
same human population that As exposure is
also associated with a significant increase in
the MMP-9/TIMP1 (tissue inhibitor of
metalloproteinase) ratio, indicative of on-
going inﬂammation (Josyula et al. 2006). Our
analysis did not show a correlation between
MMP-9/TIMP1 and RAGE (data not
shown). However activation of cellular RAGE
has been shown to increase MMP-9 expres-
sion (Goova et al. 2001). 
There are several other proteins of note
that we have identified as being altered after
As exposures. These include GST-omega-1,
enolase-1, apolipoprotein A-1, and peroxi-
redoxin-6. GST-omega-1 has been shown to
Lantz et al.
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Table 4. Regression models and β coefﬁcients by individuals.
No. Adjusted R 2 Outcome variable Predictor variables β coefﬁcient p-Value
47 0.210 ln RAGEa Town 0.011 0.973
Diabetes 0.761 0.079
BMI 0.091 0.002
Total urinary inorganic As –0.021 0.016
aExcludes regression outliers. p-Value < 0.05 is signiﬁcant.
Figure 1. Sputum RAGE concentrations determined using ELISA techniques and plotted as a function of
total urinary As levels. Because of the overlap in urinary As, data from all individuals from both Ajo and
Tucson are plotted; outliers have been excluded. The regression line is from analysis detailed in Table 4
and shows a decrease in sputum RAGE as a function of urinary As.
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40 60 80 100 120be an As reductase, having the ability to reduce
AsV species to the more toxic AsIII species
(Zakharyan et al. 2001). Although it would be
expected to be a cytoplasmic protein, other
GSTs have been identified in BALF by pro-
teomic techniques (Wattiez and Falmagne
2005). Increased levels of enolase-1 and
decreased levels of apolipoprotein A-1 have
been previously described as markers of lung
cancer (Rutters et al. 2006). The presence of
two distinct spots for enolase-1 indicates that
posttranslational modiﬁcations may be present,
as has been reported (Tanaka et al. 1995).
Peroxiredoxin-6 is highly expressed in the lung
and is localized predominantly in alveolar
epithelial type II cells and in Clara cells. It has
a dual function as a glutathione peroxidase and
as a phospholipase A2 and is induced by oxida-
tive stress (Kim et al. 2003). Alterations in per-
oxiredoxin-6 suggests that As is playing a role
by inducing oxidative stress. In addition, both
RAGE and peroxiredoxin-6 are highly
expressed in the distal airways and in alveoli.
This also suggests that the distal lung may be a
site of action for As. Proteomics analysis has
shown differences in these proteins in mice,
but we have not yet analyzed these proteins in
humans. We expect that a single biomarker
protein will not be sufﬁcient to fully describe
the response to As exposure. Rather, a panel of
proteins will be required to more comprehen-
sively determine the effects of As exposure.
Although the majority of analyses in
human diseases have been done using ELISA
techniques for specific proteins, the use of
proteomics as a tool to search for disease
markers in BALF has previously been pro-
posed (Wattiez and Falmagne 2005; Wattiez
et al. 2003). We recognize that many of the
proteins seen in these proteomic analyses are
also seen in our experiments. This means that
quantitative analysis of levels of expression
for these proteins must be performed to eval-
uate their usefulness as good biomarkers.
However, RAGE has not been previously
identified as a potential biomarker in lung-
lining fluid, and thus, our finding of altera-
tions in RAGE in animal models and humans
in response to As is unique and supports its
identiﬁcation as a pulmonary biomarker of As
exposure or effect.
Conclusion
We used a proteomics approach to evaluate
As-induced changes in BAL proteins in mice.
Six proteins were identified as potential bio-
markers. Based on these findings, we tested
one of the proteins, RAGE, and found that it
was reduced in induced sputum from humans
exposed to As in their drinking water. Using a
proteomics approach permits a relatively
unbiased evaluation of numerous proteins
simultaneously, making it possible to detect
molecular changes associated with low-dose
environmental exposure before the develop-
ment of clinically apparent disease. We plan
to use patterns of changes in multiple proteins
measured simultaneously to deﬁne modes or
mechanisms of action that can be compared
among toxicants and compared among bio-
logical systems including humans, human cell
lines, and rodents. 
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